Skip to main content
OpenTrials
Completed

NCT Number: NCT01683565

Preemie Tots: A Pilot Study to Understand the Effects of Prematurity in Toddlerhood

The purpose of this study is to examine whether supplementation with certain polyunsaturated fatty acids can help development and behavior of children born preterm.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 month–39 month

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Nationwide Children's Hospital

Columbus, Ohio, 43205, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Child born at less than or equal to 29 completed weeks' gestation;
  • Child between 18 months, 0 days and 38 months, 30 days old chronological age;
  • Child admitted to NICU and/or had a Neonatology Clinic follow up visit scheduled.
  • Child showing some autistic symptoms;
  • Child between the 5th and 95th percentiles (per WHO growth chart) for weight at his/her most recent hospital visit;
  • English spoken in the home, demonstrate ability to communicate in English well-enough to understand study, informed consent, and study questionnaires; and
  • Have informed consent on file.

Exclusion criteria

  • Consume LCPUFA supplement drops, chews, powders, Pediasure, or fatty fish more than 2x per week;
  • Unable to tolerate venipuncture;
  • Any major malformation that would preclude participation;
  • Cerebral Palsy (quadriparesis only);
  • Deafness;
  • Blindness;
  • Bleeding disorder;
  • Type I diabetes;
  • Fragile X Syndrome, Rett Syndrome, Angelman Syndrome, Tuberous Sclerosis;
  • Non febrile seizure in the last month without a clear and resolved etiology;
  • Feeding problem that may inhibit full participation;
  • Known fish allergy;
  • Known canola/rapeseed allergy or sensitivity; or
  • Recorded score of <70 on Bayley Cognitive Section within the past year.

Treatment and study plan

LCPUFA Oil Supplement

Drug

2.5mL per day for 90 days

Daily Dose: EPA (338mg) + DHA (225mg) + GLA (83mg) + OA (200mg)

Canola Oil Placebo

Other

2.5mL per day for 90 days

Primary outcomes

  1. Child Behavior - Pervasive Developmental Disorders Screening Test-II Stage 2

    Time frame: Baseline to 90 days post randomization

    The Pervasive Developmental Disorders Screening Test-II stage 2 (PDDST-II) is a 14-item measure designed to discriminate Autism Spectrum Disorders from a related non-autistic developmental disorder in children ages 12 to 48 months old. The min score is 0 and the max score is 14. Scores equal to or greater than five yield a positive screen for autism. PDDST-II scores were measured at baseline and then again at study completion (90 days post randomization). The scores were calculated as the PDDST-II value at 90 days minus the PDDST-II value at baseline.

  2. Child Behavior-Brief Infant-Toddler Social and Emotional Assessment (BITSEA)

    Time frame: Baseline to 90 days post randomization

    Brief Infant-Toddler Social and Emotional Assessment (BITSEA) is a 42 item tool that is useful for identifying social-emotional problems and/or deficits in children. BITSEA includes the following subscales: Competence (11 Items, min score:0, max score:22), problem behaviors--dysregulation (8 items, min score:0, max score:16) , externalizing (6 items, min score:0, max score:12), internalizing (8 items, min score:0, max score:16), Autism Spectrum Disorder (17 Items, min score:0, max score:34), and Red Flags (14 items, min score:0, max score:28).The questions overlap and the problem subscale is a combination of dysregulation, externalizing, and internalizing. Higher problem scores indicate greater levels of social-emotional/behavioral problems. Lower Competence scores indicate possible delay/deficit. Scores were measured at baseline and then again at study completion (90 days post randomization). The change in BITSEA scores were calculated as the value at 90 days - the value at baseline.

Secondary outcomes

  1. Fatty Acid

    Time frame: Baseline to 90 days post randomization

    The secondary outcome measures in this trial involve an examination of change in fatty acids from the first study visit to the final study visit.

Other outcomes

  1. Feasibility: Future Full-scale Multi-site Study

    Time frame: Pre-baseline to 90 days post randomization

    Feasibility of a future full-scale multi-site study is assessed by examining the number of children screened, the proportion of these children who screen positive for ASD, the number of children who agree to participate in the trial, the number of children who return for the second and third study visits, baseline differences in individual fatty acids between the intervention and comparison groups, and adherence to the assigned treatment.

Sponsors and collaborators

Lead sponsor

Sarah Keim

Other

Collaborators

  • Cures Within Reach
  • Marci and Bill Ingram Fund for Autism Spectrum Disorders Research

Registry information

Important dates

Study start
2012
Primary completion
2015
Study completion
2017
First posted
Sep 12, 2012
Registry last updated
Jan 3, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.